Endo Health Plans to Acquire NuPathe in $105M Deal

Endo Health Solutions plans to acquire migraine treatment maker NuPathe for $105 million, according to a Sun Herald report.

Advertisement

Endo Health focuses on branded and generic drugs, devices and services for pain management, urology and endocrinology.

NuPathe, a developer of neuroscience solutions, announced earlier this year that its first commercial product — a migraine treatment patch called Zecuity — earned approval from the U.S. Food and Drug Administration.

More Articles on Supply Chain:

FUJIFILM to Launch EHR-Certified Solution to Help Radiologists Achieve MU Stage 2
Amerinet Names Edwin Herrington VP, Acute-Care Sales
The Best of Both Worlds: 7 Ways to Approach ASC Preference Item Management Without Sacrificing Physician Satisfaction

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.